San Diego Archives - MedCity News https://medcitynews.com/tag/san-diego/ Healthcare technology news, life science current events Wed, 27 Sep 2023 17:56:12 +0000 en-US hourly 1 https://wordpress.org/?v=6.3.1 https://medcitynews.com/uploads/2021/03/cropped-mblue-32x32.png San Diego Archives - MedCity News https://medcitynews.com/tag/san-diego/ 32 32 40682243 Once a Blockbuster Prospect, Is Travere’s Kidney Drug on Track to Become a Bust? https://medcitynews.com/2023/09/chronic-kidney-disease-travere-therapeutics-filspari-clinical-trial/ https://medcitynews.com/2023/09/chronic-kidney-disease-travere-therapeutics-filspari-clinical-trial/#respond Thu, 21 Sep 2023 20:30:59 +0000 https://medcitynews.com/?p=649473 Urinary system, bladder, kidney

Seven months after Travere Therapeutics’ flagship drug received accelerated FDA approval in a rare kidney disease, the molecule has fallen short of the key goal of its confirmatory test. It’s the small molecule’s second Phase 3 failure this year.

]]>
https://medcitynews.com/2023/09/chronic-kidney-disease-travere-therapeutics-filspari-clinical-trial/feed/ 0 649473
FDA Rejects ARS Pharma’s Nasal Spray Alternative to Injectable Epinephrine https://medcitynews.com/2023/09/fda-rejection-nasal-spray-epinephrine-epipen-alternative-ars-pharma/ https://medcitynews.com/2023/09/fda-rejection-nasal-spray-epinephrine-epipen-alternative-ars-pharma/#respond Wed, 20 Sep 2023 17:51:20 +0000 https://medcitynews.com/?p=649275 FDA sign, headquarters

ARS Pharmaceuticals frames its intranasal epinephrine spray as a needle-free alternative to products such as EpiPen. Though this spray won the backing of an FDA advisory committee, the agency is now requiring that ARS Pharma run another study to support a regulatory submission.

]]>
https://medcitynews.com/2023/09/fda-rejection-nasal-spray-epinephrine-epipen-alternative-ars-pharma/feed/ 0 649275
Sanofi Puts Up $125M to Partner on Oral Drug That Could Be Dupixent’s Successor https://medcitynews.com/2023/07/sanofi-puts-up-125m-to-partner-on-oral-drug-that-could-be-dupixents-successor/ https://medcitynews.com/2023/07/sanofi-puts-up-125m-to-partner-on-oral-drug-that-could-be-dupixents-successor/#respond Thu, 20 Jul 2023 17:13:17 +0000 https://medcitynews.com/?p=642153

Sanofi is interested in Recludix Pharma’s approach to treating inflammation with an oral small molecule that targets a protein thought to be undruggable. If it works, the drug could have safety and dosing advantages over currently available biologic drugs, including blockbuster Sanofi drug Dupixent.

]]>
https://medcitynews.com/2023/07/sanofi-puts-up-125m-to-partner-on-oral-drug-that-could-be-dupixents-successor/feed/ 0 642153
Here’s Why Novartis Is Paying $500M to Acquire a Preclinical RNA Startup https://medcitynews.com/2023/07/heres-why-novartis-is-paying-500m-to-acquire-a-preclinical-rna-startup/ https://medcitynews.com/2023/07/heres-why-novartis-is-paying-500m-to-acquire-a-preclinical-rna-startup/#respond Wed, 19 Jul 2023 00:06:13 +0000 https://medcitynews.com/?p=642030

Novartis’s acquisition of DTx Pharma brings a lead program for a rare disease with no FDA-approved therapies. But the deal could also help the pharma giant bring new RNA therapies to new places in the body, a top Novartis executive explained.

]]>
https://medcitynews.com/2023/07/heres-why-novartis-is-paying-500m-to-acquire-a-preclinical-rna-startup/feed/ 0 642030
Travere Therapeutics Drug for Rare Kidney Disease Falls Short in Pivotal Test https://medcitynews.com/2023/05/biotech-rare-kidney-disease-clinical-trial-failure/ https://medcitynews.com/2023/05/biotech-rare-kidney-disease-clinical-trial-failure/#respond Tue, 02 May 2023 17:37:18 +0000 https://medcitynews.com/?p=633309

Sparsentan failed to meet the main goal of a Phase 3 test in focal segmental glomerulosclerosis (FSGS). Nevertheless, Travere Therapeutics says the totality of data points to patient improvement in the rare kidney disorder and the biotech will talk with regulators about a potential path forward.

]]>
https://medcitynews.com/2023/05/biotech-rare-kidney-disease-clinical-trial-failure/feed/ 0 633309
Merck’s $11B Prometheus Acquisition Brings IBD Drug & Precision Medicine Platform https://medcitynews.com/2023/04/mercks-11b-prometheus-acquisition-brings-ibd-drug-precision-medicine-platform/ https://medcitynews.com/2023/04/mercks-11b-prometheus-acquisition-brings-ibd-drug-precision-medicine-platform/#respond Mon, 17 Apr 2023 20:17:36 +0000 https://medcitynews.com/?p=631515

Merck is acquiring Prometheus Biosciences and a lead drug candidate in development for inflammatory bowel disorders. The deal comes as Merck looks for drug prospects that could make up for revenue declines facing blockbuster seller Keytruda, which faces patent expirations in coming years.

]]>
https://medcitynews.com/2023/04/mercks-11b-prometheus-acquisition-brings-ibd-drug-precision-medicine-platform/feed/ 0 631515
Startup Function Oncology Aims to Make CRISPR Part of Next Revolution in Cancer https://medcitynews.com/2023/04/startup-function-oncology-aims-to-make-crispr-part-of-next-revolution-in-cancer/ https://medcitynews.com/2023/04/startup-function-oncology-aims-to-make-crispr-part-of-next-revolution-in-cancer/#respond Wed, 12 Apr 2023 17:20:00 +0000 https://medcitynews.com/?p=630903

Function Oncology goes beyond next-generation sequencing with a CRISPR-based technology that identifies targets for a patient’s cancer regardless of whether or not they are mutated. Now out of stealth, the company will present data validating its approach during the American Association for Cancer Research annual meeting.

]]>
https://medcitynews.com/2023/04/startup-function-oncology-aims-to-make-crispr-part-of-next-revolution-in-cancer/feed/ 0 630903
Patient Deaths and Partial Hold Prompt Gossamer Bio to Stop Work on Cancer Drug https://medcitynews.com/2023/04/patient-deaths-and-partial-hold-prompt-gossamer-bio-to-stop-work-on-cancer-drug/ https://medcitynews.com/2023/04/patient-deaths-and-partial-hold-prompt-gossamer-bio-to-stop-work-on-cancer-drug/#respond Tue, 04 Apr 2023 15:30:30 +0000 https://medcitynews.com/?p=630102 brain x-ray image

Two fatalities were reported in an early-stage study testing a Gossamer Bio drug intended to treat a rare cancer affecting the central nervous system. Due to the adverse events and a partial FDA clinical hold, Gossamer has decided to stop work on the program.

]]>
https://medcitynews.com/2023/04/patient-deaths-and-partial-hold-prompt-gossamer-bio-to-stop-work-on-cancer-drug/feed/ 0 630102
FTC Orders Illumina to Divest Grail, Says Deal Stifles Cancer Test Competition https://medcitynews.com/2023/04/ftc-orders-illumina-to-divest-grail-says-deal-stifles-cancer-test-competition/ https://medcitynews.com/2023/04/ftc-orders-illumina-to-divest-grail-says-deal-stifles-cancer-test-competition/#respond Mon, 03 Apr 2023 21:53:23 +0000 https://medcitynews.com/?p=630024 Federal Trade Commission, FTC

The Federal Trade Commission has ordered Illumina to divest Grail, the liquid biopsy company it acquired for more than $7 billion. The agency said Illumina’s proposed remedies are insufficient and the tie-up is likely to reduce competition in the R&D and commercialization of new cancer tests.

]]>
https://medcitynews.com/2023/04/ftc-orders-illumina-to-divest-grail-says-deal-stifles-cancer-test-competition/feed/ 0 630024
FDA Approval of Travere Kidney Disease Drug Sets Up Blockbuster Expectations https://medcitynews.com/2023/02/fda-approval-of-travere-kidney-disease-drug-sets-up-blockbuster-expectations/ https://medcitynews.com/2023/02/fda-approval-of-travere-kidney-disease-drug-sets-up-blockbuster-expectations/#respond Wed, 22 Feb 2023 01:31:27 +0000 https://medcitynews.com/?p=624826

Travere Therapeutics drug Filspari won accelerated FDA approval to treat a rare disorder that can lead to kidney failure. The small molecule is also in late-stage testing for another rare kidney disease; analysts say each indication represents a blockbuster opportunity.

]]>
https://medcitynews.com/2023/02/fda-approval-of-travere-kidney-disease-drug-sets-up-blockbuster-expectations/feed/ 0 624826
MD Anderson’s Tech Puts Replay on Fast Path to Clinic With TCR NK Cell Therapies https://medcitynews.com/2023/02/md-andersons-tech-puts-replay-on-fast-path-to-clinic-with-tcr-nk-cell-therapies/ https://medcitynews.com/2023/02/md-andersons-tech-puts-replay-on-fast-path-to-clinic-with-tcr-nk-cell-therapies/#respond Wed, 15 Feb 2023 17:21:44 +0000 https://medcitynews.com/?p=624340

Syena, the latest company formed by startup creator Replay, is developing cancer treatments based on a type of immune cell called a natural killer cell. This NK cell therapy technology, licensed from The University of Texas MD Anderson Cancer Center, could overcome many of the limitations facing first-generation cell therapy.

]]>
https://medcitynews.com/2023/02/md-andersons-tech-puts-replay-on-fast-path-to-clinic-with-tcr-nk-cell-therapies/feed/ 0 624340
Scripps Spinout Belharra Unveils $130M to Catch Next Big Wave of Drug Discovery https://medcitynews.com/2023/01/scripps-spinout-belharra-unveils-130m-to-catch-next-big-wave-of-drug-discovery/ https://medcitynews.com/2023/01/scripps-spinout-belharra-unveils-130m-to-catch-next-big-wave-of-drug-discovery/#respond Mon, 16 Jan 2023 19:51:39 +0000 https://medcitynews.com/?p=620584

Versant Ventures-backed Belharra Therapeutics has launched with $130 million in funding and a partnership with Roche subsidiary Genentech. The startup’s technology analyzes proteins in the context of the entire cell, enabling it to discover molecules that bind to targets previously deemed undruggable.

]]>
https://medcitynews.com/2023/01/scripps-spinout-belharra-unveils-130m-to-catch-next-big-wave-of-drug-discovery/feed/ 0 620584
Neurocrine Commits $175M to Voyager in New Neuro Gene Therapy Alliance https://medcitynews.com/2023/01/neurocrine-commits-175m-to-voyager-in-new-neuro-gene-therapy-alliance/ https://medcitynews.com/2023/01/neurocrine-commits-175m-to-voyager-in-new-neuro-gene-therapy-alliance/#respond Mon, 09 Jan 2023 23:37:17 +0000 https://medcitynews.com/?p=619852

Neurocrine Biosciences is paying $175 million up front for rights to a preclinical Voyager Therapeutics gene therapy that could put the biotech in competition with Eli Lilly among other companies. Voyager could earn up to $4.2 billion in milestone payments.

]]>
https://medcitynews.com/2023/01/neurocrine-commits-175m-to-voyager-in-new-neuro-gene-therapy-alliance/feed/ 0 619852
FDA Approval of Mirati Lung Cancer Drug Sets Stage for Competition With Amgen https://medcitynews.com/2022/12/fda-approval-of-mirati-lung-cancer-drug-sets-stage-for-competition-with-amgen/ https://medcitynews.com/2022/12/fda-approval-of-mirati-lung-cancer-drug-sets-stage-for-competition-with-amgen/#respond Tue, 13 Dec 2022 18:50:26 +0000 https://medcitynews.com/?p=617065

Amgen’s Lumakras became the first FDA-approved drug that addresses the elusive KRAS mutation, but Mirati believes its newly approved therapy, Krazati, could be better. The small molecule’s features include the ability to penetrate into the brain, where it can address cancer that has spread to the central nervous system.

]]>
https://medcitynews.com/2022/12/fda-approval-of-mirati-lung-cancer-drug-sets-stage-for-competition-with-amgen/feed/ 0 617065
New Gene Therapy Biotech Telaria Launches With Rare Skin Disease Focus https://medcitynews.com/2022/11/new-gene-therapy-biotech-telaria-launches-with-rare-skin-disease-focus/ https://medcitynews.com/2022/11/new-gene-therapy-biotech-telaria-launches-with-rare-skin-disease-focus/#respond Tue, 22 Nov 2022 00:09:00 +0000 https://medcitynews.com/?p=614437

Telaria is developing a gene therapy for the rare skin disorder recessive dystrophic epidermolysis bullosa. The company was formed by Replay, a gene therapy biotech that forms subsidiaries that leverage its platform technologies for writing and delivering genetic medicines.

]]>
https://medcitynews.com/2022/11/new-gene-therapy-biotech-telaria-launches-with-rare-skin-disease-focus/feed/ 0 614437
Penn spinout Capstan aims for next cell therapy frontier: in vivo cell engineering https://medcitynews.com/2022/09/penn-spinout-capstan-aims-for-next-cell-therapy-frontier-in-vivo-cell-engineering/ https://medcitynews.com/2022/09/penn-spinout-capstan-aims-for-next-cell-therapy-frontier-in-vivo-cell-engineering/#respond Wed, 14 Sep 2022 16:53:05 +0000 https://medcitynews.com/?p=604291

Capstan Therapeutics, a University of Pennsylvania spinout, is now out of stealth with technology that could enable new medicines that work by engineering cells inside of a patient. Penn biotech pioneers Carl June and Drew Weissman are among the scientific co-founders of this startup, which aims to develop therapies for fibrosis, cancer, inflammation, and genetic diseases.

]]>
https://medcitynews.com/2022/09/penn-spinout-capstan-aims-for-next-cell-therapy-frontier-in-vivo-cell-engineering/feed/ 0 604291
Brain-focused Neurocrine buys a biotech to broaden its scope in hormone disorders https://medcitynews.com/2022/08/brain-focused-neurocrine-buys-a-biotech-to-broaden-its-scope-in-hormone-disorders/ https://medcitynews.com/2022/08/brain-focused-neurocrine-buys-a-biotech-to-broaden-its-scope-in-hormone-disorders/#respond Tue, 30 Aug 2022 17:10:04 +0000 https://medcitynews.com/?p=602182 brain in hands

Neurocrine Biosciences is acquiring Diurnal Group, a U.K-based biotech that has commercialized two endocrine disorder drugs. Neurocrine’s top-selling product is a blockbuster drug for an involuntary muscle movement disorder.

]]>
https://medcitynews.com/2022/08/brain-focused-neurocrine-buys-a-biotech-to-broaden-its-scope-in-hormone-disorders/feed/ 0 602182
FDA turns down Acadia Pharma drug for Alzheimer’s psychosis; new trial needed https://medcitynews.com/2022/08/fda-turns-down-acadia-pharma-drug-for-alzheimers-psychosis-new-trial-needed/ https://medcitynews.com/2022/08/fda-turns-down-acadia-pharma-drug-for-alzheimers-psychosis-new-trial-needed/#respond Sun, 07 Aug 2022 12:57:10 +0000 https://medcitynews.com/?p=598502

Acadia Pharmaceuticals drug Nuplazid failed to win FDA approval for the treatment of psychosis in Alzheimer’s disease patients. The regulator said that the data submitted were not from an adequate and well-controlled study and the company must run another clinical trial.

]]>
https://medcitynews.com/2022/08/fda-turns-down-acadia-pharma-drug-for-alzheimers-psychosis-new-trial-needed/feed/ 0 598502
Startup aiming to push boundaries of gene therapy nets $55M in seed cash https://medcitynews.com/2022/07/startup-aiming-to-push-boundaries-of-gene-therapy-nets-55m-in-seed-cash/ https://medcitynews.com/2022/07/startup-aiming-to-push-boundaries-of-gene-therapy-nets-55m-in-seed-cash/#respond Mon, 25 Jul 2022 17:32:32 +0000 https://medcitynews.com/?p=596789 dna, genomics

Private equity firm KKR teamed up with OMX Ventures to lead the seed investment in Replay, a company developing a suite of technologies that could overcome capacity limitations of adeno-associated viruses used for genetic medicines delivery. Duchenne muscular dystrophy is among the disease targets of the new startup.

]]>
https://medcitynews.com/2022/07/startup-aiming-to-push-boundaries-of-gene-therapy-nets-55m-in-seed-cash/feed/ 0 596789
Vertex builds up pipeline of type 1 diabetes cell therapies with $320M buyout https://medcitynews.com/2022/07/vertex-builds-up-pipeline-of-type-1-diabetes-cell-therapies-with-320m-buyout/ https://medcitynews.com/2022/07/vertex-builds-up-pipeline-of-type-1-diabetes-cell-therapies-with-320m-buyout/#respond Mon, 11 Jul 2022 18:34:44 +0000 https://medcitynews.com/?p=594587

Vertex Pharmaceuticals already has a cell therapy candidate for type 1 diabetes but the company says acquiring rival ViaCyte will provide it with complementary assets and technologies. The two companies already share a partner in common: both have therapeutic candidates that use the gene-editing capabilities of CRISPR Therapeutics.

]]>
https://medcitynews.com/2022/07/vertex-builds-up-pipeline-of-type-1-diabetes-cell-therapies-with-320m-buyout/feed/ 0 594587
Human Longevity strikes a SPAC deal to go public and fuel U.S., global expansion https://medcitynews.com/2022/06/human-longevity-strikes-a-spac-deal-to-go-public-and-fuel-u-s-global-expansion/ https://medcitynews.com/2022/06/human-longevity-strikes-a-spac-deal-to-go-public-and-fuel-u-s-global-expansion/#respond Tue, 21 Jun 2022 21:28:19 +0000 https://medcitynews.com/?p=592208

Human Longevity, Inc., a startup founded by genomics pioneer J. Craig Venter, plans to join the public markets via a SPAC merger. If the business combination closes, HLI would receive about $345 million for continued commercialization of its platform that uses genomics, AI, and other technologies for early disease detection and other strategies intended to help people live longer.

]]>
https://medcitynews.com/2022/06/human-longevity-strikes-a-spac-deal-to-go-public-and-fuel-u-s-global-expansion/feed/ 0 592208
November will bring political change. Will it also change drug prices and PDUFA? https://medcitynews.com/2022/06/november-will-bring-political-change-will-it-also-change-drug-prices-and-pdufa/ https://medcitynews.com/2022/06/november-will-bring-political-change-will-it-also-change-drug-prices-and-pdufa/#respond Thu, 16 Jun 2022 06:08:27 +0000 https://medcitynews.com/?p=591791

Drug prices are on the minds of patients and politicians. The November election is expected to tip the balance of power in Congress and a panel held during the Biotechnology Innovation Organization’s annual meeting discussed what that change could mean for drug price legislation.

]]>
https://medcitynews.com/2022/06/november-will-bring-political-change-will-it-also-change-drug-prices-and-pdufa/feed/ 0 591791
BIO panel: How Covid-19 is preparing us to better respond to the next pandemic https://medcitynews.com/2022/06/bio-panel-how-covid-19-is-preparing-us-to-better-respond-to-the-next-pandemic/ https://medcitynews.com/2022/06/bio-panel-how-covid-19-is-preparing-us-to-better-respond-to-the-next-pandemic/#respond Wed, 15 Jun 2022 07:50:33 +0000 https://medcitynews.com/?p=591530

Biopharmaceutical companies and public health officials have learned a great deal about pandemic response in the last two years. A panel discussion during the annual meeting of the Biotechnology Innovation Organization explored some of the lessons from Covid-19 and how they can prepare us for the next pandemic.

]]>
https://medcitynews.com/2022/06/bio-panel-how-covid-19-is-preparing-us-to-better-respond-to-the-next-pandemic/feed/ 0 591530
BMS bets $4.1B on lung cancer drug that could best products from Pfizer, Roche https://medcitynews.com/2022/06/bms-bets-4-1b-on-lung-cancer-drug-that-could-best-products-from-pfizer-roche/ https://medcitynews.com/2022/06/bms-bets-4-1b-on-lung-cancer-drug-that-could-best-products-from-pfizer-roche/#respond Fri, 03 Jun 2022 19:07:17 +0000 https://medcitynews.com/?p=590024

Bristol Myers Squibb is splashing out $4.1 billion to acquire Turning Point Therapeutics, a clinical-stage biotech whose lead drug is currently in pivotal testing as a treatment for certain lung cancers. Recently reported preliminary data suggest the small molecule could have advantages over currently available drugs in the same class from rivals Pfizer and Roche.

]]>
https://medcitynews.com/2022/06/bms-bets-4-1b-on-lung-cancer-drug-that-could-best-products-from-pfizer-roche/feed/ 0 590024
Aiming to treat Parkinson’s by replacing neurons, Aspen Neuroscience nabs $147M https://medcitynews.com/2022/05/aiming-to-treat-parkinsons-by-replacing-neurons-aspen-neuroscience-nabs-147m/ https://medcitynews.com/2022/05/aiming-to-treat-parkinsons-by-replacing-neurons-aspen-neuroscience-nabs-147m/#respond Mon, 09 May 2022 19:15:51 +0000 https://medcitynews.com/?p=586719

Aspen Neurosciences is developing a cell therapy that uses a patient’s own stem cells to develop a personalized treatment for Parkinson’s disease. The approach is slightly different than that of Bayer, whose experimental Parkinson’s cell therapy is made from stem cells sourced from healthy donors.

]]>
https://medcitynews.com/2022/05/aiming-to-treat-parkinsons-by-replacing-neurons-aspen-neuroscience-nabs-147m/feed/ 0 586719
Biotech startup Eclipsebio emerges to shed light on RNA drug research https://medcitynews.com/2022/03/biotech-startup-eclipse-bio-emerges-to-shed-light-on-rna-drug-research/ https://medcitynews.com/2022/03/biotech-startup-eclipse-bio-emerges-to-shed-light-on-rna-drug-research/#respond Wed, 16 Mar 2022 02:44:29 +0000 https://medcitynews.com/?p=577443 mRNA

Scientists developing new RNA drugs need to understand how proteins bind to these molecules. Eclipsebio’s technology provides that analysis and the biotech startup now has a Series A round of funding to scale up its business.

]]>
https://medcitynews.com/2022/03/biotech-startup-eclipse-bio-emerges-to-shed-light-on-rna-drug-research/feed/ 0 577443
Creyon Bio gets some green for a new take on AI and genetic meds R&D https://medcitynews.com/2022/03/creyon-bio-gets-some-green-for-a-new-take-on-ai-and-genetic-meds-rd/ https://medcitynews.com/2022/03/creyon-bio-gets-some-green-for-a-new-take-on-ai-and-genetic-meds-rd/#respond Sun, 13 Mar 2022 13:01:47 +0000 https://medcitynews.com/?p=576837

Creyon Bio is the latest company to launch with artificial intelligence technology for drug R&D. The startup claims its technology can provide sufficient safety and toxicity data to enable a therapy to bypass the animal research currently needed before clinical trials.

]]>
https://medcitynews.com/2022/03/creyon-bio-gets-some-green-for-a-new-take-on-ai-and-genetic-meds-rd/feed/ 0 576837
Endeavor Bio adds $101M to test ex-Eli Lilly, Roche drug in cancer & lung fibrosis https://medcitynews.com/2022/02/endeavor-bio-adds-101m-to-test-ex-eli-lilly-roche-drug-in-cancer-lung-fibrosis/ https://medcitynews.com/2022/02/endeavor-bio-adds-101m-to-test-ex-eli-lilly-roche-drug-in-cancer-lung-fibrosis/#respond Tue, 08 Feb 2022 00:25:04 +0000 https://medcitynews.com/?p=570142

Endeavor BioMedicines aims to kill two birds with one stone—that stone being a small molecule drug. Taladegib targets a cell signaling pathway associated with both cancer and idiopathic pulmonary fibrosis, and the biotech will apply its Series B round toward clinical tests of the molecule on both fronts.

]]>
https://medcitynews.com/2022/02/endeavor-bio-adds-101m-to-test-ex-eli-lilly-roche-drug-in-cancer-lung-fibrosis/feed/ 0 570142
Kura Oncology leukemia clinical trial to resume after FDA lifts partial hold https://medcitynews.com/2022/01/kura-oncology-leukemia-clinical-trial-to-resume-after-fda-lifts-partial-hold/ https://medcitynews.com/2022/01/kura-oncology-leukemia-clinical-trial-to-resume-after-fda-lifts-partial-hold/#respond Fri, 21 Jan 2022 17:32:17 +0000 https://medcitynews.com/?p=567073

The FDA placed the partial hold on the study last November following a patient death suspected to be linked to a known complication of leukemia therapies. Kura Oncology said it has reached agreement with the FDA on a mitigation strategy for that complication.

]]>
https://medcitynews.com/2022/01/kura-oncology-leukemia-clinical-trial-to-resume-after-fda-lifts-partial-hold/feed/ 0 567073
Blueprint Medicines to buy cancer drug startup with potential edge over Takeda, J&J targeted therapies https://medcitynews.com/2021/11/blueprint-medicines-to-buy-cancer-drug-startup-with-potential-edge-over-takeda-jj-targeted-therapies/ https://medcitynews.com/2021/11/blueprint-medicines-to-buy-cancer-drug-startup-with-potential-edge-over-takeda-jj-targeted-therapies/#respond Mon, 29 Nov 2021 18:18:05 +0000 https://medcitynews.com/?p=560204

Blueprint Medicines is paying $250 million up front to acquire Lengo Therapeutics, developer of targeted cancer therapies. The startup’s lead drug candidate is on track to begin human testing in non-small cell lung cancer, and Blueprint believes the small molecule has advantages over new targeted therapies from Johnson & Johnson and Takeda Pharmaceutical.

]]>
https://medcitynews.com/2021/11/blueprint-medicines-to-buy-cancer-drug-startup-with-potential-edge-over-takeda-jj-targeted-therapies/feed/ 0 560204